CapsoVision, Inc. develops and markets capsule endoscopy technology for gastrointestinal imaging. The company’s flagship product, CapsoCam Plus®, is a wire-free panoramic capsule endoscope for small-bowel visualization with cloud-based or direct capsule video retrieval. News about CV commonly covers commercial adoption, quarterly financial results, account growth, product development and the company’s Nasdaq-listed public-company activity.
Recurring updates also include FDA submissions for AI-assisted capsule endoscopy tools, development work on CapsoCam Colon™, CMOS sensor development with Canon, private placement financing, investor conference participation and corporate governance or finance leadership changes.
CapsoVision (NASDAQ: CV) will release its third quarter 2026 financial results after market close on November 12, 2026. The company will host a conference call and live webcast that day at 1:30 pm PT / 4:30 pm ET to discuss the results and provide a corporate update. A live and archived webcast will be available on its Investor Relations Events page.
CapsoVision (NASDAQ: CV) will present at the 20th Annual LD Micro Main Event on October 21, 2026. The presentation is scheduled for 9:00–9:25 am PT at the Luxe Sunset Boulevard Hotel in Los Angeles. CEO Johnny Wang, finance executive David Garcia and global sales executive Doug Atkinson will participate. The format includes a company presentation and one-on-one investor meetings, with the presentation webcast live.
CapsoVision (CV) received FDA clearance on September 25, 2026, for AI Highlights, its AI-assisted reading tool for CapsoCam Plus.
The tool is designed to help physicians review capsule endoscopy studies performed for suspected small bowel bleeding in adults and children over two years old. It marks images with suspected abnormal lesions for priority review, with the aim of reducing review time. AI Highlights integrates with CapsoView software and supports connected CapsoCloud workflows. CapsoVision launched the tool internationally earlier this year, including in the European Union. It is intended for trained healthcare professionals and does not replace a gastroenterologist’s diagnostic interpretation or, where applicable, tissue-sample analysis.
CapsoVision (CV) will participate in two upcoming investor conferences in September 2026, featuring its executive leadership team.
The company will present at the H.C. Wainwright 28th Annual Global Investment Conference, with an on-demand presentation available starting Friday, September 11, 2026 at 7:00 a.m. ET, and 1x1 investor meetings on Monday, September 14, 2026 in New York City. CapsoVision will also attend the 5th Annual ROTH Healthcare Opportunities Conference on Tuesday, September 29, 2026, conducting 1x1 investor meetings.
The on-demand presentation will be accessible on the Events page in the investor relations section of CapsoVision’s website for 90 days. Investors interested in arranging one-on-one meetings are directed to contact their H.C. Wainwright or Roth representatives, or email the company at Investors@CapsoVision.com.
CapsoVision (NASDAQ: CV) reported second quarter 2026 revenue of $3.6 million, up about 10% year over year, driven by a 13% increase in CapsoCam Plus capsule volume, partially offset by roughly 3% lower average selling prices. Gross profit was $1.9 million, with gross margin at 51% versus 55% a year ago.
Operating expenses rose to $9.5 million, mainly from clinical trials, Canon development work, public company costs, and stock-based compensation, leading to a net loss of $7.5 million. Cash and cash equivalents were $9.1 million on June 30, 2026. CapsoVision launched its AI Highlights feature internationally, continues advancing CapsoCam Colon toward a planned fourth-quarter 2026 510(k) submission, is enrolling a pancreatic cancer UGI study, added David S. Shields, M.D., to its board, and entered a $100 million at-the-market equity program with Cantor.
CapsoVision (NASDAQ: CV) announced the international launch of AI Highlights, an AI-assisted review feature for small bowel capsule endoscopy using the CapsoCam Plus system. The tool is available within CapsoView and, where applicable, CapsoCloud in markets authorized under regional regulatory requirements, including the European Union MDR.
AI Highlights uses an algorithm to analyze video frames captured by CapsoCam Plus and flag frames with suspected clinically relevant findings for physician review. It is intended to support, not replace, clinical judgment and is available only to trained healthcare professionals. The feature has not been cleared by the U.S. FDA and is not available for sale in the United States.
CapsoVision (NASDAQ: CV) announced it will release its second quarter 2026 financial results on Thursday, August 13, 2026, after the market close. On the same day, the company will host a conference call and live webcast at 1:30 pm PT / 4:30 pm ET to discuss results and provide a corporate update. Investors can join by dialing the provided US numbers with conference ID 9178774, or via the live and archived webcast available on the Events page of the Investor Relations section of CapsoVision’s website.
Visteon (NASDAQ:VC) reported second quarter 2026 net sales of $960 million, slightly below $969 million a year earlier, with 4% growth-over-market driven by launch ramps and regional execution. Net income attributable to Visteon was $49 million, or $1.80 diluted EPS. Adjusted EBITDA was $116 million, a 12.1% margin, supported by customer commercial recoveries and cost discipline, partly offset by higher supplier costs and continued engineering investments.
Operating cash flow for the quarter was $37 million, with free cash flow of $12 million. For the first six months of 2026, operating cash flow totaled $43 million and adjusted free cash flow was an outflow of $3 million. Visteon ended the quarter with $650 million in cash, $299 million of debt and a net cash position of $351 million. The company booked approximately $2.0 billion in new business and launched 24 new products across 11 customers.
Visteon also announced a $200 million accelerated share repurchase under its existing $800 million authorization, expected to complete early in the fourth quarter of 2026, aligning with its capital allocation focus on shareholder returns and growth investment.
CapsoVision (Nasdaq: CV) appointed gastroenterology specialist David S. Shields, M.D. to its Board of Directors, effective July 1, 2026, succeeding Joanne C. Imperial, M.D., who will remain as an independent clinical consultant.
Dr. Shields brings over 40 years of gastroenterology experience, nearly two decades with capsule endoscopy, and a long advisory role to CapsoVision as the company advances its AI-enabled capsule endoscopy platform, including CapsoCam Plus®, CapsoCam Colon™ and future clinical programs.
CapsoVision (NASDAQ: CV) reported first quarter 2026 revenue of $2.8 million, stable year over year. Gross profit was $1.3 million with a 48% gross margin, impacted by U.S. trade policies and tariffs.
Operating expenses rose to $8.4 million, driven by CMOS sensor development with Canon and clinical trials. Cash and equivalents totaled $17.9 million following a $14 million private placement. The company highlighted growing CapsoCam Plus® usage, key GI network renewals, upcoming FDA review of its AI-assisted reading feature, and progress on colon and pancreatic cancer programs.